MAM
Havells unveils ‘#LetsEndDarkness Talks’ in a new digital campaign
Mumbai: Havells India has started a video series #LetsEndDarkness (LED) Talks under a newly launched campaign, celebrating inspiring stories of people who have eliminated darkness from their lives despite obstacles and challenges.
Content partner by Unhide and conceptualised by Netter, the campaign features five inspiring real-life influencers who overcame the dusk and triumphed in their lives.
The central concept that lies behind the campaign idea is that with determination, individuals can rise to their fullest potential despite the challenges they face and grow beyond the constraints of their current circumstances.
The five influencers who will be a part of this campaign video are: India women’s cricketer, Smriti Mandhana, who has established herself in a sport that is primarily known to be male-dominated. Athlete Deepa Malik, who became the first Indian woman to compete in the Paralympic Games. Photographer Vicky Roy, a ragpicker at New Delhi railway station who ran away from home, studied photography and eliminated darkness from his life. Dr. Ruth John Paul, who took birth in a male body with a feminine spirit and transformed herself. She has worked her way up to become the first doctor at India’s first transgender clinic. Pooja Dasgupta, a single parent, who has overcome her unhappy marriage. Dasgupta raised her child single-handedly and emerged stronger despite the unforeseen challenges.
The campaign video begins with a black screen with a voiceover of the influencer in the backdrop and moves on to a frame of light and illumination where they begin narrating their story. The videos are shot in long-form stories for the website and in a crisper short format for social media channels. The video series will run for six weeks on all social media platforms, including Facebook, Instagram, and YouTube, and will be amplified on digital platforms.
A true warrior doesn’t need a sword. All she needs is the light from within – especially when her name itself means spreading bright light!
Stay tuned to watch her challenging life journey on Havells Lighting #LetsEndDarknessMoments.
#LetsEndDarkness #HavellsLighting pic.twitter.com/CC5eIEMjRg— Havells (@havellsindia) August 22, 2022
Here we are with the episode 2 of Havells Lighting #LetsEndDarknessMoments. Watch how @DeepaAthlete, the first Indian woman to win a medal in the Paralympic Games, accepted the challenges & turned the tides of misfortune & rewrote her fate.
Know more-https://t.co/cd4hVwB63r pic.twitter.com/LoGBxnUklt— Havells (@havellsindia) August 24, 2022
Commenting on the launch of the new campaign, Marketing Havells India executive vice president Rohit Kapoor said, “The campaign thought of “LED Talks” aims at taking the high ground and thought leadership in the category, which is above product and feature-based advertising. We are proud that the first campaign video amplified by Smriti Mandhana on her Instagram handle has already garnered more than 1,18,000 likes.”
“The campaign is another step towards creating remarkable storytelling that will help coherently communicate the brand’s narrative for change with LED (light-emitting diode) to a completely different proposition where the three letters of ‘LED’ stand for “Let’s End Darkness,”” he added.
Havells India president & SBU head Parag Bhatnagar added, “With the new “LED Talks” campaign, we want to spread positivity among people and hope that they resonate with it in a powerful yet humble way. The campaign establishes real-life victory testimonies that people have achieved despite obstacles and hardship owing to their valour. A core message of ‘enlightenment within’ has been used in the campaign with a strong emotional and socially responsible message. We are hopeful that people will be inspired by the new campaign and feel motivated to achieve their aspirations.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
